HPV DNA Tissue Testing is peformed on FFPE tissue. It uses PCR and fragment analysis for qualitative detection and genotyping of human papillomavirus (HPV) low risk types 6/11 and high risk types 16, 18, 31, 33, 45, and 58. When detected, specific genotypes are identified except for 6 and 11 which cannot be distinguished from each other and are reported as positive for the combination 6/11.
HPV DNA testing on FFPE tissue in head and neck squamous cell carcinomas (HNSCC), anogenital, and cervical lesions provides a complementary or alternative method to testing by p16 IHC or HPV ISH. In anogenital specimens, testing can distinguish presence of low-risk HPV types 6 and 11, associated with benign warts, from high-risk types which are associated with approximately 90% of anal cancers, 40% of vaginal cancers, and 40% of penile cancers. HPV is detected in up to 60-70% of oropharyngeal cancers and approximately 30% of HNSCC overall. HPV status serves as a prognostic marker head and neck cancer. Patients with HPV-positive cases have improved response to treatment and longer survival than patients with HPV-negative tumors in clinical trials.
- FFPE solid tumor tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at thickness of 5-10 microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Use cold pack for transport, making sure cold pack is not in direct contact with specimen.
5 - 7 DAYS